Regular article

Inhibition of osteoclastogenesis by osteoblast-like cells genetically engineered to produce interleukin-10

Kazuki Fujioka^{1,2}, Tsunao Kishida¹, Akika Ejima¹, Kenta Yamamoto^{1,3}, Wataru Fujii², Ken Murakami², Takahiro Seno^{2,4}, Aihiro Yamamoto², Masataka Kohno², Ryo Oda⁵, Toshiro Yamamoto³, Hiroyoshi Fujiwara⁵, Yutaka Kawahito², and Osam Mazda^{1*}

Departments of ¹Immunology, ²Inflammation and Immunology, ³Dental Medicine, ⁴Rheumatic Diseases and Joint Function, and ⁵Orthopaedics, Kyoto Prefectural University of Medicine, Kyoto, Japan

*Corresponding author at the Department of Immunology, Kyoto Prefectural University of Medicine, Kamikyo, Kyoto 602-8566, Japan; TEL: +81-75-251-5330; FAX: +81-75-251-5331; E-mail: mazda@koto.kpu-m.ac.jp

Abbreviations: RA, rheumatoid arthritis; iOBs, induced osteoblast-like cells; IL-10-iOBs, IL-10-producing induced osteoblast-like cells; OCN, osteocalcin; OPN, osteopontin; BSP, bone sialoprotein; ALP, alkaline phosphatase

1 Abstract

2 Bone destruction at inflamed joints is an important complication associated with rheumatoid arthritis
3 (RA). Interleukin-10 (IL-10) may suppress not only inflammation but also induction of osteoclasts
4 that play key roles in the bone destruction. If IL-10-producing osteoblast-like cells are induced from
5 patient somatic cells and transplanted back into the destructive bone lesion, such therapy may
6 promote bone remodeling by the cooperative effects of IL-10 and osteoblasts. We transduced mouse
7 fibroblasts with genes for IL-10 and Runx2 that is a crucial transcription factor for osteoblast
8 differentiation. The IL-10-producing induced osteoblast-like cells (IL-10-iOBs) strongly expressed
9 osteoblast-specific genes and massively produced bone matrix that were mineralized by calcium
10 phosphate in vitro and in vivo. Culture supernatant of IL-10-iOBs significantly suppressed induction
11 of osteoclast from RANKL-stimulated Raw264.7 cells as well as LPS-induced production of
12 inflammatory cytokine by macrophages. The IL-10-iOBs may be applicable to novel cell-based
13 therapy against bone destruction associated with RA.

14

15 Keywords: Interleukin-10, osteoblast, inflammation, rheumatoid arthritis, gene therapy

16 _____

1 Introduction

2 Rheumatoid arthritis (RA) is a chronic disorder characterized by systemic inflammation and multiple
3 arthritis. In addition to synovial lesions, the bones at the inflamed joints are **destroyed by** activated
4 osteoclasts, resulting in severe pain, deformity and disability in patients. Although the pathogenesis
5 of RA remains to be fully understood, crucial roles are played by proinflammatory cytokines such as
6 IL-1 β , IL-6, and TNF- α that are secreted from activated T cells and macrophages [1]. These
7 cytokines also provoke synovial fibroblasts to produce RANKL, which subsequently induces
8 osteoclasts to cause destruction of cartilage and bone [2]. **Monoclonal antibodies and soluble**
9 **receptors that block the pro-inflammatory cytokine signals have been used as biological agents and**
10 drastically improved the clinical outcome of RA; however, various adverse events may be associated
11 with the therapies such as serious infection [3]. Meanwhile, any current medication has not
12 succeeded in healing destructive bone, and surgical intervention is required to treat patients with
13 severe joint destruction [4,5]. Therefore, it is necessary to develop a new therapeutic approach to
14 suppress inflammation and achieve repair of the destroyed bones without causing undesirable
15 adverse events.

16 IL-10 is a profound immunosuppressive cytokine produced by macrophages, T cells, and certain
17 subsets of B cells and dendritic cells (DCs) [6]. Moreover, IL-10 remarkably prevents generation of
18 osteoclasts through the inhibition of NFATc1 expression [7]. Therefore, IL-10 is regarded as a

1 promising cytokine applicable to anti-rheumatic therapy, due to its powerful activities to suppress
2 inflammation as well as osteoclastogenesis.

3 A number of reports indicated that systemic administration of IL-10 may provide significant
4 therapeutic benefit to animal models of experimental arthritis [8,9,10]. Moreover, IL-10 suppresses
5 production of inflammatory cytokines such as IL-1 β and TNF- α by synovial fluid macrophages of
6 RA patients [11]. In previous clinical trials, IL-10 administration was reported safe and well
7 tolerated, but its therapeutic efficacy for RA was unsatisfactory [12,13]. This may be due to
8 insufficiency of distribution of IL-10 at the joint lesions after systemic administration of the cytokine.
9 Systemic administration of a higher dose of IL-10 could potentially cause cancer development,
10 chronic infection, and Th2-dependent autoimmune disorders that represent lupus-like symptoms [14].
11 Therefore, local delivery of IL-10 to the inflammatory regions is desirable. Some studies have shown
12 that the cells genetically modified to produce IL-10 were effective in treating experimental arthritis
13 in animals [15,16].

14 Osteoblasts are crucially involved in bone formation and remodeling through production of
15 calcified bone matrix. We hypothesized that if osteoblast-like cells are engineered to produce IL-10
16 and transplanted into the destructed bone tissue, such a procedure may offer a great deal of
17 therapeutic benefits to RA patients due to remodeling of bone tissue as well as suppression of
18 articular inflammation. Osteoblast-like cells can be induced from mouse fibroblasts by transducing

1 the Runx2 gene that plays an essential role in osteoblast differentiation [17], and this sort of
2 technology may enable production of patient-specific, induced osteoblast-like cells (iOBs) that are
3 suitable for transplantation therapy.

4 However, effect of IL-10 on osteoblast differentiation remains controversial. IL-10 gene knockout
5 mice showed loss of alveolar bone and osteopenia-like phenotypes including bone mass reduction
6 [18,19,20]. In contrast, van Vlasselaer et al. reported that administration of exogenous IL-10
7 inhibited the osteoblast differentiation from mouse bone marrow cells through the inhibition of
8 TGF- β 1 [21,22].

9 In this context, we examined whether co-transduction of Runx2 and IL-10 genes successfully
10 induced mouse fibroblasts into IL-10-producing osteoblast-like cells with capability to produce bone
11 matrix. We also tested whether the genetically modified cells inhibited production of
12 pro-inflammatory cytokines by activated macrophages as well as induction of osteoclasts.

13 _____

1 Materials and Methods

2 **Cells**

3 Mouse embryonic fibroblasts (MEFs) were obtained from Balb/c embryos at the gestational age of
4 day 13.5 by digestion with collagenase (NB4G®; Serva, Heidelberg, Germany). MEFs were cultured
5 in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL
6 streptomycin, and 10 mM non-essential amino acids (standard medium). Raw264.7, A20, and
7 SaOS2 were purchased from RIKEN cell bank (Tsukuba, Japan). Yac1 was maintained in our
8 laboratory. SCC-7 was kindly gifted by Dr. Oya at the Department of Therapeutic Radiology and
9 Oncology, Kyoto University, Japan.

10

11 **Retrovirus vectors**

12 The cDNA fragments encoding mouse Runx2 and IL-10 genes were obtained from pFLCI-mouse
13 Runx2 and pFLCI-mouse IL-10 plasmids (Danaform, Kanagawa, Japan), respectively, and inserted
14 into the pMX-puro with GeneArt Seamless Cloning and Assembly (Life Technologies, Carlsbad,
15 CA). The resultant retrovirus vector plasmids, pMX-mRunx2.puro and pMX-mIL10.puro, were
16 transfected into the Plat-E packaging cell line with X-treme Gene 9 (Roche Diagnostics, Basel,
17 Switzerland). Twenty-four hours later, the culture medium was replaced by fresh one, and after
18 incubation for another 24 hours, culture supernatant containing retrovirus vectors was harvested.

1

2 Induction of osteoblasts

3 MEFs were seeded onto a 24-well plate at a density of 1.5×10^4 per well. On the next day, the
4 retrovirus vector suspension was supplemented with 4 $\mu\text{g/mL}$ polybrene (Nacalai Tesque, Kyoto,
5 Japan) and added to the cells, which were subsequently cultured in the standard medium
6 supplemented with 100 nM dexamethasone (Nacalai Tesque), 50 $\mu\text{g/mL}$ L-ascorbic acid (Nacalai
7 Tesque), and 10 mM β -glycerophosphate (Tokyo Chemical Industry, Tokyo, Japan)(osteogenic
8 medium). The culture was continued for 2 to 4 weeks, while the medium was changed every 2 days.

9

10 Alizarin red S staining and staining by von Kossa's method

11 For Alizarin red S staining, cells were fixed with 95% ethanol for 10 minutes at room temperature.
12 After washing with distilled water, cells were stained with Alizarin red S solution (Sigma-Aldrich, St.
13 Louis, MO) for 30 to 45 minutes, followed by another washing with distilled water. Stained area was
14 calculated with ImageJ [23]. For von Kossa staining, cells were fixed in 10% neutral buffered
15 formalin for 10 minutes at room temperature. After 3 times washing with distilled water, 5% silver
16 nitrate solution (ScyTek Laboratories, Logan, UT) was added to the cells, which were subsequently
17 exposed to ultra violet for 30 to 60 minutes. Culture dishes were rinsed 3 times with distilled water,
18 and incubated with 5% sodium thiosulfate solution (ScyTek Laboratories) for 2 minutes.

1

2 Alkaline phosphatase (ALP) staining

3 ALP activity was determined by ALP staining using a Leukocyte Alkaline Phosphatase Kit
4 (Sigma-Aldrich) following the manufacture's instruction. Briefly, cells were fixed with 60%
5 acetone/40% citrate. After washing with deionized water, cells were stained with a diazonium salt
6 solution containing fast violet blue salt and 4% of naphthol AS-MX phosphate alkaline solution for 1
7 hour under protection from light.

8

9 Immunofluorescence staining

10 Cells were fixed with 4% paraformaldehyde at 4°C for 30 minutes, followed by washing with 0.02%
11 Tween-20/PBS. After blocking, cells were washed and incubated with FITC-conjugated rat
12 anti-mouse IL-10 (final concentration was 1:100)(eBioscience, San Diego, CA) and
13 Cy5.5-conjugated rabbit anti-mouse osteocalcin (OCN)(final concentration was 1:100)(Bioss,
14 Woburn, MA) antibodies. On the next day, cells were washed, and observed under a fluorescence
15 microscope.

16

17 Real time RT-PCR

18 Cells were homogenized in Isogen 2 (Nippongene, Tokyo, Japan), and total RNA was harvested by

1 the phenol guanidinium acid-based procedure. After reverse transcription using ReverTra Ace qPCR
2 RT Master Mix (TOYOBO, Osaka, Japan), cDNA served as template for real time PCR using
3 Applied Biosystems 7300 Real-Time PCR System. The primers and dye probe for osteocalcin
4 (OCN)(Bglap: Mm03413826_mH), osteopontin (OPN)(SPP1: Mm00436767_m1), bone sialoprotein
5 (BSP)(IBSP: Mm00492555_m1), alkaline phosphatase (Alpl: Mm00492555_m1), IL-1 β (Il1b:
6 Mm00434228_m1), telomerase reverse transcriptase (Tert: Mm00436931_m1) and β -actin
7 (Mm00607939-m1) genes were purchased from Applied Biosystems (Carlsbad, CA). The primer
8 sequences for TNF- α and IL-6 genes were as follows: TNF- α forward, 5'-tcttctcattcctgtgtgg-3';
9 TNF- α reverse, 5'-ggctctggccatagaactga-3'; IL-6 forward, 5'-gctaccaaactggatataatcagga-3', IL-6
10 reverse, 5'-ccaggtagctatgttactccagaa-3'. Corresponding probes were purchased from Roche Applied
11 Science (Basel, Switzerland) (Universal Probe Library: TNF- α #49, IL-6#6). Samples were incubated
12 at 95°C for 10 minutes for an initial denaturation, followed by forty PCR cycles that consisted of
13 denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 minute. β -actin gene was
14 regarded as endogenous standard and normalization was calculated using RQ software. All
15 experiments were performed in triplicate.

16

17 ELISA

18 The concentration of IL-10 was measured using Mouse IL-10 Ready SET Go ELISA kit

1 (eBioscience) according to the manufacturer's instruction.

2

3 Induction of osteoclasts

4 Raw264.7 cells obtained from the RIKEN cell bank were plated in 12-well plates at a density of $1 \times$

5 10^4 cells/well, and cultured in a standard medium supplemented with or without 100 ng/mL of

6 RANKL (PeproTech, Rocky Hill, NJ). In some wells, culture supernatants that had been harvested

7 from MEFs, induced osteoblast-like cells (iOBs), and IL-10-producing iOBs (IL-10-iOBs) were

8 added. The culture medium was replaced by a fresh one on day 3. Six days after the initiation of the

9 culture, cells were subjected to tartrate-resistant acid phosphatase (TRAP) staining using the TRAP

10 kit (Primary Cell, Sapporo, Japan). Briefly, the cells were fixed with 10% neutral buffered formalin

11 for 5 minutes, followed by incubation at 37°C for 1 hour in 50 mmol/L tetratate buffer containing

12 substrate. After washing with distilled water, the TRAP-positive multi-nuclear cells were regarded as

13 mature osteoclasts.

14

15 Activation of peritoneal macrophages

16 6 to 8 week-old female Balb/c mice were intraperitoneally injected with 2 mL of thioglycolate

17 medium. Three days later, mice were sacrificed and 5 mL of PBS was injected into the peritoneal

18 cavity. After gentle massage, the peritoneal exudate cells were retrieved and seeded into 12-well

1 plates at 1.5×10^6 cells per well. After 2 hours of culture, the floating cells were removed, and
2 residual adherent cells were cultured for 24 hours in the presence of supernatants of MEFs, iOBs and
3 IL-10-iOBs. Cells were then stimulated with LPS (100 ng/mL)(Invitrogen, Carlsbad, CA) for 2
4 hours.

5

6 Contact inhibition

7 SaOS2 cells and MEFs that had been transduced with Runx2 and IL-10 genes were seeded in 60 mm
8 culture dishes at a density of 1.5×10^5 cells/dish, and cultured for 15 days without trypsinization and
9 reseeding. Cell morphology was observed under phase-contrast microscopy.

10

11 Transplantation

12 Twenty-four hours after infection with the Runx2 and/or IL-10 retrovirus vectors, MEFs, iOBs and
13 IL-10-iOBs were seeded on hydrogel scaffold (MedGel® SP; MedGEL, Tokyo, Japan) at a density
14 of 3.5×10^4 cells/scaffold. After pre-culture for 2 days in osteogenic medium, the cells were
15 subcutaneously transplanted into the flank of 6-week-old female Balb/c mice. Four weeks later, the
16 graft was excised and cryosectioned. Mineralization status of the specimens was estimated by
17 Alizarin red staining and staining by the von Kossa's method as above. To examine tumor formation,
18 IL-10-iOBs or MEFs that had been cultured in osteogenic medium for 2 days were subcutaneously

1 inoculated into 7-week-old male SCID/NOD mice with or without hydrogel scaffold at a dose of
2 either 3.5×10^4 or 3.0×10^6 /mouse.

3

4 Statistical Analysis

5 All the data were analyzed by Student's unpaired *t*-test, and $p < 0.05$ was considered statistically
6 significant.

7

8

1 **Results**

2 IL-10 gene transduction did not prevent Runx2-mediated induction of osteoblast-like cells from
3 fibroblasts

4 To generate IL-10-secreting osteoblast-like cells, we transduced primary mouse embryonic
5 fibroblasts (MEFs) with Runx2 and IL-10 genes via retrovirus vectors, and analyzed the phenotypes
6 of the resultant cells (IL-10-iOBs) in comparison with those of the osteoblast-like cells induced by
7 transduction of Runx2 gene alone (iOBs). The ALP staining indicated that both IL-10-iOBs and
8 iOBs showed high activities of ALP, an early stage marker of osteoblast differentiation, 10 days after
9 the gene transduction (Fig. 1A, top). Alizarin red S staining unveiled that the IL-10-iOBs produced
10 mineralized bone matrix as massively as iOBs on day 20, whereas un-transduced MEFs failed to
11 show any significant staining (Fig. 1A, middle). Calculation of the Alizarin red S-stained areas also
12 demonstrated comparable degrees of calcification in IL-10-iOBs and iOBs cultures (data not shown).
13 Staining by the von Kossa's method also confirmed massive calcium deposition by IL-10-iOBs and
14 iOBs, but not by MEFs (Fig. 1A, bottom).

15 To further confirm the osteoblast-like characteristics of the cells, we examined expression of
16 osteoblast marker genes 15 days after the gene transfer (Fig. 1B). Quantitative RT-PCR analysis
17 demonstrated that IL-10-iOBs expressed similar or even higher levels of mRNA for the osteocalcin
18 (OCN), osteopontin (OPN), bone sialoprotein (BSP) and ALP genes as iOBs.

1 These data strongly suggested that IL-10 gene transfer did not hamper osteoblast-like phenotypic
2 conversion of MEFs.

3

4 IL-10-iOBs produced IL-10 at a high level.

5 To assess the IL-10 production by IL-10-iOBs, we performed quantitative RT-PCR 15 days after the
6 initiation of the osteoblast induction. The cells expressed a high level of IL-10 mRNA, which was
7 not the case with iOBs and MEFs (Fig. 2A). We also harvested the supernatants of the IL-10-iOBs
8 and measured IL-10 concentrations by ELISA, which showed robust IL-10 secretion from the cells
9 on days 1 and 2 (Fig. 2B).

10 Because IL-10-iOBs potentially contained heterogeneous populations, further experiments were
11 performed to clarify whether the IL-10 was produced by the cells with osteoblast-like features.

12 Immunofluorescence staining of IL-10-iOBs was performed to visualize OCN and IL-10 on day 14.

13 As shown in Fig. 2C, OCN and IL-10 were co-localized in the same cells, indicating that IL-10 was
14 produced by the osteoblast-like cells.

15

16 Conditioned medium of IL-10-iOBs suppressed induction of osteoclasts

17 To estimate whether the IL-10 secreted from IL-10-iOBs was capable of inhibiting
18 osteoclastogenesis, we collected the culture supernatants of the IL-10-iOBs, iOBs and MEFs, and

1 examined their effect on the mouse macrophage cell line, Raw264.7, that was induced to
2 differentiate into osteoclasts by an addition of RANKL [24,25]. Six days after the induction, a
3 number of TRAP-stained multinuclear cells (MNCs) appeared in the cultures in which the
4 supernatant of MEFs or iOBs had been added (Fig. 3A). In contrast, the osteoclast-like cells were
5 hardly detectable in the culture that had received the supernatant of the IL-10-iOBs. We counted the
6 number of TRAP-positive MNCs in each group and confirmed that an addition of supernatant of
7 IL-10-iOBs significantly reduced the number of osteoclast-like cells induced from Raw264.7 cells
8 (Fig. 4B).

9

10 Conditioned medium of IL-10-iOBs suppressed production of inflammatory cytokines by activated
11 macrophages

12 We examined the effect of IL-10-iOB supernatant on cytokine production by activated macrophages.
13 The thioglycollate-elicited peritoneal macrophages were cultured with supernatant of IL-10-iOBs,
14 iOBs or MEFs, followed by stimulation with 100 ng/mL LPS. 2 hours later, mRNA levels for IL-1 β ,
15 IL-6, TNF- α and IL-10 were evaluated by real time RT-PCR. As shown in Fig. 4A, the supernatant
16 of IL-10-iOBs significantly suppressed mRNA expression of IL-1- β , IL-6 and TNF- α . Neither MEF
17 nor iOB supernatants significantly affected the expression of the pro-inflammatory cytokines, except
18 that the supernatant of iOBs significantly enhanced IL-6 mRNA expression. In sharp contrast, the

1 supernatant of IL-10-iOBs rather elevated the expression of IL-10 mRNA by the LPS-stimulated
2 macrophages.

3 These results strongly suggested that IL-10 secreted from IL-10-iOBs suppressed production of the
4 pro-inflammatory cytokines.

5 Significant bone formation in vivo by ectopically transplanted IL-10-iOBs.

6 **We** tested whether the IL-10-iOBs are capable of forming bone in vivo. The IL-10-iOBs cultured on
7 hydrogel scaffold were subcutaneously transplanted into the flank of the syngenic mice. After 4
8 weeks, histological assessment of the graft was performed, and the specimen was strongly stained
9 with Alizarin red S (Fig. 4B, lower middle). The bone formation was also confirmed by the positive
10 staining by the von Koss's method (Fig. 4B, lower right), while the HE staining did not show any
11 sign of inflammatory cell infiltration (Fig. 4B, lower left). Meanwhile, bone formation was totally
12 absent in the tissue into which MEFs had been transplanted as a control (Fig. 4B, upper).

13 Therefore, IL-10-iOBs remarkably produced a mineralized bone matrix in vivo after transplantation,
14 suggesting applicability of the cells to novel cell therapy for RA.

15 IL-10-iOBs lacked tumor-like characteristics.

16 **Finally, we examined whether IL-10-iOBs exhibited tumor cell-like features. In culture, IL-10-iOBs**

1 proliferated until they form a confluent monolayer and subsequently underwent growth arrest
2 (Supplementary Fig. 1A). This is in sharp contrast to SaOS2 osteosarcoma cells that showed loss of
3 contact inhibition. The IL-10-iOBs expressed mRNA for the telomerase reverse transcriptase
4 (TERT) gene at as low level as fibroblasts, whereas most tumor cells highly expressed TERT
5 (Supplementary Fig. 1B) [26].

6 Tumorigenic potential of IL-10-iOBs was assessed by subcutaneously inoculation into
7 immune-deficient mice. Tumor development was not seen in all the mice. Taken together, it was
8 strongly suggesting that the IL-10-iOBs did not have tumorigenicity (Supplementary Table S1).

9 _____

Discussion

In the present study, we proposed a novel therapeutic procedure for RA based on the transplantation of genetically modified osteoblast-like cells. By transducing MEFs with the genes for osteoblast differentiation factor Runx2 and potent anti-inflammatory cytokine IL-10, the established IL-10-iOBs expressed osteoblast marker genes at high levels (Fig. 1B) and massively produced mineralized bone matrix both in vitro (Fig. 1A) and in vivo (Fig. 4B), while IL-10 was also abundantly produced by the osteocalcin-positive cells (Fig. 2), strongly suggesting that IL-10 production did not interfere with Runx2-mediated induction of the osteoblast-like phenotypes. Previous reports indicated that administration of IL-10 suppressed differentiation of osteoblasts through inhibition of the TGF- β signaling [22], while TGF- β signaling contributes to osteoblast differentiation by inducing Runx2 expression [27]. Therefore, exogenous Runx2 gene may have substituted for the endogenous Runx2 that was suppressed by IL-10, resulting in restoration of the IL-10-mediated interference of osteoblast differentiation.

The supernatant of IL-10-iOBs significantly suppressed both RANKL-mediated induction of osteoclasts from Raw264.7 (Fig. 3) and production of inflammatory cytokines by LPS-activated macrophages (Fig. 4A). The anti-inflammatory and anti-osteoclast functions of the IL-10-iOBs may cooperatively ameliorate the inflammatory bone destruction at the joint lesions of RA patients, if

1 transplantation therapy using these cells is clinically applicable to RA patients in the future. An
2 extremely high production of IL-10 may cause some adverse events such as immunosuppression. To
3 limit the serum level of IL-10 not to exceed the tolerable level, patients may be transplanted with a
4 mixture of IL-10-iOBs and iOBs at an appropriate ratio.

5 The iOBs may be quite adequate for the cell-based therapy for RA, because a sufficient number of
6 iOBs with high bone formation capacity may be induced from patients' own somatic cells.
7 Fibroblasts may be particularly useful as the somatic cells to be induced into iOBs, because they can
8 be obtained from RA patients in a minimally invasive fashion and allowed to proliferate to a large
9 number in culture before induction into osteoblast-like cells. Other cells such as leukocytes may
10 become an alternative for fibroblasts, but this point should be examined in further studies. Although
11 the transduction of Runx2 gene alone fails to induce osteoblast-like phenotypic change in somatic
12 cells of human origin, this problem may be overcome by using some combinations of genes instead
13 of Runx2 gene alone, and we have already established such a procedure (Yamamoto et al., a
14 manuscript submitted for publication).

15

16 Acknowledgements

17 This work was supported by grants from the Japan Science and Technology Agency, and the
18 Japanese Ministry of Education, Culture, Sports, Science and Technology. All authors have declared

1 References

- 2 [1] I.B. McInnes, G. Schett, Cytokines in the pathogenesis of rheumatoid arthritis, *Nat. Rev.*
3 *Immunol.* 7 (2007) 429-442.
- 4 [2] Y. Wu, J. Liu, X. Feng, et al., Synovial fibroblasts promote osteoclast formation by RANKL in a
5 novel model of spontaneous erosive arthritis, *Arthritis Rheum.* 52 (2005) 3257-3268.
- 6 [3] V. Connor, Anti-TNF therapies: a comprehensive analysis of adverse effects associated with
7 immunosuppression, *Rheumatol. Int.* 31 (2011) 327-337.
- 8 [4] U. Møller Døhn, A. Boonen, M.L. Hetland, et al., Erosive progression is minimal, but erosion
9 healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year
10 investigator-initiated follow-up study using high-resolution computed tomography as the
11 primary outcome measure, *Ann. Rheum. Dis.* 68 (2009) 1585-1590.
- 12 [5] S. Finzel, J. Rech, S. Schmidt, et al., Interleukin-6 receptor blockade induces limited repair of
13 bone erosions in rheumatoid arthritis: a micro CT study, *Ann. Rheum. Dis.* 72 (2013) 396-400.
- 14 [6] M. Saraiva, A. O'Garra, The regulation of IL-10 production by immune cells, *Nat. Rev. Immunol.*
15 10 (2010) 170-181.
- 16 [7] K.E. Evans, S.W. Fox, Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression
17 and preventing its translocation to the nucleus, *BMC Cell Biol.* 8 (2007) 4.
- 18 [8] L. Ye, Z. Wen, Y. Li, et al., Interleukin-10 attenuation of collagen induced arthritis is associated

- 1 with suppression of interleukin-17 and retinoid related orphan receptor γ t production in
2 macrophages and repression of classically activated macrophages, *Arthritis Res. Ther.* 16
3 (2014) R96.
- 4 [9] N.A. Carter, E.C. Rosser, C. Mauri, Interleukin-10 produced by B cells is crucial for the
5 suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of
6 collagen-induced arthritis, *Arthritis Res. Ther.* 14 (2012) R32.
- 7 [10] M. Walmsley, P.D. Katsikis, E. Abney, et al., Interleukin-10 inhibition of the progression of
8 established collagen-induced arthritis, *Arthritis Rheum.* 39 (1996) 495-503.
- 9 [11] P.H. Hart, M.J. Ahern, M.D. Smith, et al., Comparison of the suppressive effects of
10 interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from
11 patients with inflammatory arthritis, *Immunology* 84 (1995) 536-542.
- 12 [12] K. Asadullah, W. Sterry, H.D. Volk, Interleukin-10 therapy--review of a new approach,
13 *Pharmacol. Rev.* 55 (2003) 241-269.
- 14 [13] K.W. Moore, R. de Waal Malefyt, R.L. Coffman, et al., Interleukin-10 and the interleukin-10
15 receptor, *Annu. Rev. Immunol.* 19 (2001) 683-765.
- 16 [14] E. Bijjiga, A.T. Martino, Interleukin 10 (IL-10) Regulatory Cytokine and its Clinical
17 Consequences, *J. Clin. Cell. Immunol.* S1 (2013) 007.
- 18 [15] K. Setoguchi, Y. Misaki, Y. Araki, et al., Antigen-specific T cells transduced with IL-10

- 1 ameliorate experimentally induced arthritis without impairing the systemic immune response to
2 the antigen, *J. Immunol.* 165 (2000) 5980–5986.
- 3 [16] L. Henningsson, T. Eneljung, P. Jirholt, et al., Disease-dependent local IL-10 production
4 ameliorates collagen induced arthritis in mice, *PLoS One* 7 (2012) e49731.
- 5 [17] J.E. Phillips, R.E. Guldberg, A.J. García, Dermal fibroblasts genetically modified to express
6 Runx2/Cbfa1 as a mineralizing cell source for bone tissue engineering, *Tissue Eng.* 13 (2007)
7 2029-2040.
- 8 [18] M. Claudino, T.P. Garlet, C.R. Cardoso, Down-regulation of expression of osteoblast and
9 osteocyte markers in periodontal tissues associated with the spontaneous alveolar bone loss of
10 interleukin-10 knockout mice, *Eur. J. Oral Sci.* 118 (2010) 19-28.
- 11 [19] A. Al-Rasheed, H. Scheerens, D.M. Rennick, et al., Accelerated alveolar bone loss in mice
12 lacking interleukin-10, *J. Dent. Res.* 82 (2003) 632-635.
- 13 [20] R. Dresner-Pollak, N. Gelb, D. Rachmilewitz, et al., Interleukin 10-deficient mice develop
14 osteopenia, decreased bone formation, and mechanical fragility of long bones, *Gastroenterology*
15 127 (2004) 792-801.
- 16 [21] P. Van Vlasselaer, B. Borremans, R. Van Den Heuvel, et al., Interleukin-10 inhibits the
17 osteogenic activity of mouse bone marrow, *Blood* 82 (1993) 2361-2370.
- 18 [22] P. Van Vlasselaer, B. Borremans, U. van Gorp, et al., Interleukin 10 inhibits transforming

1 growth factor-beta (TGF-beta) synthesis required for osteogenic commitment of mouse bone
2 marrow cells, J. Cell Biol. 124 (1994) 569-577.

3 [23] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis,
4 Nat. Methods 9 (2012) 671-675.

5 [24] S.G. Mohamed, E. Sugiyama, K. Shinoda, et al., Interleukin-10 inhibits RANKL-mediated
6 expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse
7 bone marrow cells, Bone 41 (2007) 592-602.

8 [25] K.E. Evans, S.W. Fox, Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1
9 expression and preventing its translocation to the nucleus, BMC Cell Biol. 8 (2007) 4.

10 [26] E. H. Blackburn, Telomerase and Cancer, Mol. Cancer Res. 3 (2005) 477-482.

11 [27] K.S. Lee, H.J. Kim, Q.L. Li, et al., Runx2 is a common target of transforming growth factor
12 beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces
13 osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12,
14 Mol. Cell. Biol. 20 (2000) 8783-8792.

15

Legends to the Figures

Figure 1: Transduction of IL-10 gene did not inhibit induction of osteoblast-like phenotypes in MEFs.

MEFs were infected with Runx2 (iOBs) and both Runx2 and IL-10 (IL-10-iOBs) retrovirus vectors.

(A) Cells were cultured for 10 days and subjected to the ALP staining (top), while the other aliquots of cells were cultured for 20 days and subjected to the Alizarin red S staining (middle) or to staining by von Kossa's method (bottom). Gross appearance (upper) and microscopic images at magnification of x 100 (lower) are shown. (B) Fourteen days after gene transfer, RNA was extracted from the cells, and qRT-PCR analysis was performed to evaluate mRNA levels for osteocalcin (OCN), osteopontin (OPN), bone sialoprotein (BSP) and ALP genes. Data represent the means $\pm$ SD (n=3). *p<0.05, **p<0.01, N.S.: Not significant.

Figure 2. IL-10-iOBs produced a large amount of IL-10.

(A) RNA was extracted from MEFs, iOBs and IL-10-iOBs 14 days after gene transduction, and qRT-PCR analysis was performed to evaluate IL-10 mRNA. Data represent the means $\pm$ SD (n=3).

**p<0.01. (B) Culture supernatants of MEFs, iOBs, and IL-10-iOBs were harvested at the indicated days, and the concentrations of IL-10 were measured by ELISA. Data represent the means $\pm$ SD

1 (n=3). **p<0.01. (C) IL-10-iOBs were immunostained using FITC-conjugated anti-IL-10 and
2 Cy5.5-conjugated anti-OCN antibodies 14 days after gene transfer. Scale bar shows 50 μ m.

3

4 **Figure 3.** Culture supernatant of IL-10-iOBs suppressed differentiation of RANKL-stimulated
5 Raw264.7 cells into osteoclasts.

6 Raw264.7 cells were cultured with RANKL and supernatant of the indicated cells. Six days later,
7 cells were subjected to TRAP staining. (A) Microscopic images at magnification of $\times 100$ are shown.
8 (B) The numbers of TRAP-positive multi-nuclear cells (MNCs) per well are plotted. Data represent
9 the means $\pm$ SD (n=3). *p<0.05, **p<0.01.

10

11 **Figure 4.** Culture supernatant of IL-10-iOBs prevented LPS-stimulated macrophages from
12 producing proinflammatory cytokines, while IL-10-iOBs produced mineralized bone matrix in vivo.

13 (A) Peritoneal macrophages were cultured with the supernatants of the indicated cells, and
14 stimulated with LPS as described in the materials and methods. Two hours later, RNA was extracted
15 from the cells and mRNA for the indicated cytokines was evaluated by qRT-PCR. Data represent the
16 means $\pm$ SD (n=3). *p<0.05, **p<0.01, N.S., Not significant. (B) MEFs were transduced with
17 Runx2 and IL-10 genes and seeded on hydrogel scaffold. After culturing for 2 days, the cells and
18 scaffold were transplanted into the flank mice. Graft was excised 4 weeks later, and tissue was

1 subjected to the indicated staining (Scale bars indicate 100 μm).

Inhibition of osteoclastogenesis by osteoblast-like cells genetically engineered to produce interleukin-10

Figures

Fig. 1

A

B

Fig. 2

C

OCN

IL-10

Merged

A **B**

Fig. 4

A **B**